Current approaches to determine the cause of acute kidney injury (AKI) in patients with cirrhosis are suboptimal. The aim of this study was to determine the utility of fractional excretion of urea (FEUrea) for the differential diagnosis of AKI in patients with cirrhosis. A retrospective analysis was performed in patients (n 5 50) with cirrhosis and ascites admitted with AKI. Using adjudicated etiology assessment as the reference standard, receiver operating curves and optimal cutoff, sensitivity (Sn), and specificity (Sp) for the diagnosis of prerenal azotemia (PRA), type 1 hepatorenal syndrome (HRS), and acute tubular necrosis (ATN) were derived. Validation was performed in an independent cohort (n 5 50) and by bootstrap analysis. A cute kidney injury (AKI) is a common complication in patients with cirrhosis, especially in those with ascites.
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(1) It occurs in approximately 20% of patients with cirrhosis admitted to the hospital (2) and is associated with increased short-term mortality. (3, 4) The principal causes of AKI in this setting include: (1) prerenal azotemia (PRA) that results from decreases in intravascular volume (e.g., aggressive diuretic treatment, diarrhea); (2) hepatorenal syndrome type 1 (HRS), AKI that is unresponsive to albumin infusion and withdrawal of diuretics in the absence of identifiable causes (5) ; and (3) acute tubular necrosis (ATN) that results from intrinsic damage.
AKI is associated with a high mortality in those with cirrhosis; it is therefore imperative to diagnose and identify the mechanism underlying AKI quickly and institute therapy quickly to maximize the potential for reversal. Early adjudication is often attempted by assessment of the clinical scenario, laboratory tests, and a challenge of albumin infusion. Historically, fractional excretion of sodium (FENa) was used to distinguish prerenal and HRS from ATN; its use is, however, confounded by the use of diuretics (6) and sepsis (7) and its clinical utility has diminished considerably. (8) In usual clinical practice, in the absence of obvious granular casts in the urinary sediment, a volume challenge is given with albumin, and if the creatinine does not improve, the differential diagnosis is narrowed to HRS versus ATN. This is suboptimal because renal function can deteriorate during this period before the correct diagnosis is made and appropriate therapy initiated. Increasing creatinine, and thus progression of AKI, has been linked to increased mortality. (9) Other biomarkers, such as neutrophil gelatinase-associated lipocalin, (10) are research tools, expensive, and unavailable to a practicing clinician. These underscore the need to develop additional clinical tools to distinguish between functional AKI (i.e., HRS and PRA) from intrinsic AKI (i.e., ATN).
Urea is filtered in the glomerulus and then largely reabsorbed in the proximal tubule and also in the distal tubule. (11, 12) Reabsorption of urea is increased by vasopressin and the renin-angiotensin-aldosterone system (RAAS). (12, 13) Fractional excretion of urea under conditions of decreased renal perfusion and increased vasopressin and RAAS, such as that observed in cirrhosis with PRA or HRS type 1, should therefore decrease. Conversely, renal tubular injury should impair reabsorption and increase its fractional excretion. Given that urea absorption is largely modulated in the proximal tubules, it is not affected by diuretics acting more distally. (7, 12) We therefore hypothesized that the fractional excretion of urea (FEUrea) could serve as a clinical aid in making an early distinction between ATN versus PRA and HRS type 1 in patients with cirrhosis and ascites presenting with AKI. The current study was designed to test this hypothesis. The aim of this study was to evaluate the diagnostic performance of FEUrea for the differential diagnosis of AKI in patients with cirrhosis and ascites presenting to a tertiary care hospital. Specifically, the ability of FEUrea to distinguish between (1) ATN versus PRA and HRS and (2) PRA versus HRS type 1 was assessed. An initial study cohort was used to develop the diagnostic model and thresholds, which were then validated in a separate cohort of subjects. The overall design was aligned with a transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) type 3 validation study and the approach conformed with TRIPOD guidance. (14) Patients and Methods
STUDY DESIGN
This was a retrospective study that was carried out at Virginia Commonwealth University Medical Center (Richmond, VA), which is a tertiary care academic center. Potential patients were identified by screening all patients with cirrhosis who were admitted for AKI (see Definitions of AKI) to a specialized hepatology inpatient unit. Those who met inclusion criteria (see Inclusion Criteria) were included for analysis. Derivation and validation of FEUrea were designed according to the TRIPOD guidelines. (13) The protocol was approved by the institutional review board at our center. endoscopic or radiological evidence of cirrhosis, history of decompensation (hepatic encephalopathy [HE], ascites, variceal bleeding, jaundice), and liver biopsy if available Age >18 years Presence of moderate or severe ascites (14) Use of either loop diuretics and/or distal diuretics until the time of admission Availability of a baseline serum creatinine as defined by the International Club of Ascites (ICA) (6) Availability of the following urine and laboratory studies within 24 hours of admission: urine sodium, urine creatinine, urine urea, urine analysis with microscopy, complete blood counts, basic metabolic profile, hepatic panel, and prothrombin time/international normalized ratio Patients excluded from analysis were those who did not meet inclusion criteria as well as the following: past liver or kidney transplant, advanced chronic kidney disease defined as serum creatinine greater than 4 mg/dL, (15) patients on acute or chronic renal replacement therapy, ambiguous diagnosis of AKI and phenotype of AKI (see Definitions section below), and patients with hepatocellular carcinoma.
DERIVATION COHORT
Subjects admitted with cirrhosis and ascites with AKI between February 2010 and September 2013 were screened for eligibility (Fig. 1) . In those that met eligibility, data were collected on the etiology of cirrhosis, demographics, mean arterial pressure (MAP), body mass index (BMI), admission laboratory data (complete blood count, metabolic panel, hepatic panel, and urinary indices mentioned above), medications (use of diuretics, nonsteroidal anti-inflammatory drugs [NSAIDs] , and beta blockers), presence of diabetes/ hypertension, a concurrent diagnosis on admission (overt HE, gastrointestinal bleeding [GIB], and infections), and presence of two or more systemic inflammatory response syndrome (SIRS) criteria. (16) Severity of cirrhosis was recorded on admission through calculation of the Model for End-Stage Liver Disease Sodium (MELDNa) (17) and Child-Turcotte-Pugh (CTP) (18) scores. Etiology of cirrhosis was categorized into viral hepatitis C (HCV), alcohol, nonalcoholic steatohepatitis (NASH), autoimmune hepatitis AIH, and other (primary biliary cholangitis, etc.). Cause of AKI (diuretic use, infections, GIB, and other) was recorded. In addition, response to therapy (see Definitions below), use of midodrine, albumin infusions, octreotide, normal saline infusions, and renal replacement therapy were recorded.
VALIDATION COHORT
One hundred seventy-seven patients were screened from October 2013 to September 2016. A total of 50 consecutive patients who met inclusion criteria were used for the validation study ( Fig. 1) . Data collected was analogous to the derivation cohort (see above).
DEFINITIONS OF AKI and ADJUDICATION OF AKI
The Acute Kidney Injury Network criteria, (19) which have been endorsed by the ICA and Acute Dialysis Quality Initiative (20) for patients with cirrhosis, were applied to identify patients with AKI. Given that urine output documentation can be unreliable, only the rise of serum creatinine 0.3 or 1.5 times baseline was utilized. Response to therapy (full, partial, and none) were defined by the ICA criteria (6) (Supporting Table S1 ).
REFERENCE STANDARD
The reference standard for assessment of FEUrea was an adjudicated diagnosis of the cause of AKI as has been used in publications. (10, 11, 21) All cases for the phenotype of AKI were evaluated by a hepatologist with a focused interest in cirrhosis-related renal disease and a nephrologist. HRS and ATN diagnoses required agreement among both services. Criteria used for the adjudication included the ICA (5) and Kidney Disease Improving Global Outcomes clinical practice guidelines. (16) These adjudications were performed by the hepatologist and nephrologist without any knowledge about the FEUrea.
CONTEXT OF USE
The current studies were performed to evaluate the diagnostic performance of FEUrea in patients with cirrhosis and ascites admitted to a tertiary care hospital with AKI. Testing was performed to distinguish between (1) ATN versus PRA and HRS type 1 and (2) PRA and HRS type 1. The potential decisions to be made based on such distinctions would be volume replacement for PRA, volume correction with vasoconstrictor therapy for HRS type 1, and renal replacement therapy as needed for ATN.
CALCULATION OF FEUrea
Using admission values of serum urea, serum creatinine, spot measurement of urine creatinine, and spot measurement of urine urea, FeUrea was calculated as follows:
urine creatinine 4 serum creatinine ð Þ 3 100%
STATISTICAL ANALYSIS
Distribution of demographic variables, etiology of cirrhosis, presence of diabetes/hypertension, medications (nonsteroidal anti-inflammatory and beta blockers), BMI, severity of liver cirrhosis (MELD-Na and CTP), baseline serum creatinine (Scr), baseline serum blood urea nitrogen (BUN), admission Scr, admission BUN, admission MAP, serum sodium (Na), urine Na, urine creatinine, urine urea, SIRS, FEUrea, and response to therapy are described. Continuous variables are presented as mean 6 SD and median interquartile range (IQR) where deemed appropriate. Categorical variables are presented as percentages. Differences across groups with respect to categorical variables were analyzed using chi-square and Fisher's exact tests, whereas continuous variables were analyzed using the nonparametric Kruskal-Wallis test. A nominal P value of less than or equal to 0.05 was considered significant.
To evaluate the diagnostic accuracy of FEUrea, the area under receiver operating characteristic (AUROC) was constructed for the following diagnoses: (1) ATN versus non-ATN, (2) HRS type 1 versus non HRS, and (3) PRA versus HRS type 1. The Youden index was used to determine the optimal cutoffs for each group. Using this optimal cutoff, sensitivity (Sn), specificity (Spp), negative predictive value (NPV), positive predictive value (PPV), negative likelihood ratio (NLR), and positive likelihood ratio (PLR) were calculated. Performances of cut-off values at a fixed sensitivity of 90% and a specificity of 90% were also investigated. The optimal cutoffs identified in the derivation cohort were then applied to the validation cohort to determine Sn, Sp, NPV, PPV, NLR, and PLR for the aforementioned diagnostic studies. The entire cohort was then also bootstrapped for internal validation by resampling of the entire cohort. Average accuracy statistics (Sn, Sp, NPV, PPV, NLR, and PLR) across 1,000 bootstrap repetitions were calculated. Statistical analysis was performed using SPSS software for Windows (version 24; SPSS, Inc., Chicago, IL) and SAS (version 9.4; SAS Institute Inc., Cary, NC).
Results

PATIENT CHARACTERISTICS
AKI phenotype in the derivation:validation cohorts (n:n) was adjudicated as follows: PRA 21:21, HRS 18:15, and ATN: 11:14 (Tables 1 and 2 ). Clinical characteristics of both cohorts are summarized in Tables 1 and 2 . There were no statistical differences found between the derivation cohort and validation cohort with respect to demographic and clinical variables (Supporting Table S3 ). Patients in derivation and validation cohorts had advanced liver disease with mean MELD-Na scores of 27.41 6 7.65 and 29.28 6 7.77, respectively. MELD-Na scores were found to be statistically different between all three AKI phenotypes in the derivation cohort (P 5 0.010) and in the validation cohort (P 5 0.045). Median urine sodium, urine creatinine, and urine urea were significantly different across all phenotypes of AKI in both cohorts as well (Tables 1 and 2 
HOSPITALIZATION DETAILS
A concurrent diagnosis of overt HE (n 5 15) and infection (n 5 20) were present on admission in the derivation cohort. This was similar in the validation cohort (n 5 16 and n 5 23, respectively). Furthermore, infections were also reported to be the most frequent identifiable cause of AKI in both cohorts, followed by diuretic-induced volume depletion (n 5 14 in both). Concurrent diagnosis of GIB was negligible in both cohorts (n 5 2 and n 5 2, respectively).
DIAGNOSTIC ACCURACY OF FEUrea
Derivation Cohort
ATN VERSUS NON-ATN
The AUROC for FEUrea was 0.96 (95% confidence interval [CI], 0.91, 1.00). Using the Youden index, the optimal cutoff was determined to be 33.41%. A value greater than 33.41% predicted ATN with 100% Sn and 85% Sp (Table 3) . When Sp was fixed at 90%, Sn of FEUrea was 91% (optimal cutoff, 36.20%; NPV, 97%; PPV, 71%). Similarly, when Sn was fixed at 90%, Sp was preserved at 93% (optimal Abbreviation: NSBB, nonselective beta blocker.
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cutoff, 37.70%; NPV, 97%; PPV, 77%; Supporting Table S4 ).
HRS VERSUS NON-HRS
The AUROC for FEUrea was 0.87 (95% CI, 0.78, 0.97), and the optimal cut-off point was 28.16%. A value greater than 28.16% predicted non-HRS with a Sn of 75% and Sp of 83% (Table 3) . When Sp was fixed at 90%, Sn decreased to 53% (cutoff, 32.86%; NPV, 51%; PPV, 89%), and, similarly, when Sn was fixed at 90%, Sp decreased to 61% (cutoff, 21.40%; NPV, 79%; PPV, 81%).
PRA VERSUS HRS
The AUROC for FEUrea was 0.81 (95% CI, 0.67, 0.95), and the optimal cut-off point was determined to 3 (14) 2 (13) . At a fixed Sp of 90%, there was a significant drop in Sn to 29% (cutoff, 32.86%; NPV, 51%; PPV, 75%). Sp, NPV, and PPV were similar to the optimal cut-off point when Sn was fixed at 90% (Supporting Table S4 ).
Validation Cohort
Using the optimal cutoffs identified in the derivation cohort, diagnostic accuracy was maintained for ATN versusnon-ATN (Sn, 93%; Sp, 97%), HRS versus non-HRS (Sn, 63%; Sp, 100%), and PRA versus HRS (Sn, 68%; Sp, 80%; Table 4 ).
INTERNAL VALIDATION
Applying the optimal cutoffs identified in the derivation cohort, diagnostic accuracy was calculated for FEUrea across the entire cohort (test and validation) using 1,000 bootstrap repetitions. Sn and Sp was found to be preserved for ATN versus non-ATN. Sn was found to be slightly decreased in the HRS versus non-HRS and PRA versus HRS groups; however, this was accompanied with a concurrent rise in specificity (Table 5) .
Discussion
In this study, we have demonstrated that FEUrea has excellent diagnostic ability in differentiating structural AKI (ATN) from functional AKI (HRS and PRA) within 24 hours of admission in patients with decompensated cirrhosis and ascites. The diagnostic utility of FEUrea was further validated in an independent cohort of patients and showed high diagnostic accuracy with a Sn and Sp exceeding >90%. Furthermore, we were able to demonstrate its ability in separating HRS from non-HRS and PRA with good accuracy.
Urea is a primary osmolyte in urine and more than half of the urinary osmolality is supplied by urea when concentrated urine is formed. (13) The majority of its filtered load is absorbed in the proximal tubule and distally in the inner medulla collecting ducts through urea transporters that are influenced by vasopressin and aldosterone. (13) During states of antidiuresis, water is osmotically absorbed in the proximal tubule, causing a progressive increase in urea concentration downstream toward the collecting duct. Consequently, when urea reaches the inner medullary collecting duct, urea exits through urea transporters (urea transporters A1 and A3) toward the inner medullary interstitium and gets trapped because of the low effective blood flow from the countercurrent exchange that is supplied by the vasa-recta. (22, 23) In the presence of vasopressin, urea permeability is significantly higher, allowing urea to accumulate in the interstitium at high concentrations in an effort to equilibrate the high urea concentration in the collecting duct lumen. (13) As a result of these physiological mechanisms of urea handling, FEUrea is dependent on the structural integrity of the tubules, vasopressin/aldosterone's absorptive influence, but also, to a great extent, on the filtration fraction of urea and urine output. (24) For example, when the filtration fraction of urea is severely reduced, as in ATN, less urea is filtered, resulting in a lower urine urea concentration. In contrast, in prerenal AKI, the filtration fraction is increased, which leads to a much higher urea concentration in the urine as compared to ATN. (7, 12, 24) Concurrently, when decreased urine output is the result of avid water reabsorption, level of urinary creatinine increases inversely to urine output. (7, 25) Thus, a high urine creatinine concentration identifies whether oliguria is the result of avid water reabsorption, as in PRA and to a greater extent HRS versus loss of function (i.e., ATN), where the urinary creatinine concentration is much lower. Therefore, these biological considerations support our findings of a higher FEUrea cut-off for ATN (>33%) compared to lower cut-off values for PRA (<33% and >21%) and HRS (<21% ; Table 3 ).
Furthermore, we found that our cut-off values for FEUrea were much lower compared to patients without cirrhosis. (7) This is likely attributed to the increased secretion of vasopressin and underproduction of urea that is prominent in cirrhosis.
Interestingly, we found that urine urea concentration was much lower in HRS when compared to PRA. The reasons for this are probably multifactorial. For example, to a certain degree, the filtration fraction has been found to be reduced in HRS, (26, 27) suggesting an element of tubular damage. This finding corroborates with past studies, (11, 28) proposing that there is a likely overlap between HRS and milder forms of ATN. Moreover, coupled with avid water absorption (indicated by a high urine creatinine concentration; Tables  1 and 2) , and perhaps increased urea absorption in the proximal and distal tubule (through vasopressin), this could explain why FEUrea levels were much lower than PRA levels.
Early adjudication between the etiologies of AKI in decompensated cirrhosis is imperative given that it has management and prognostic implications. (2, 29, 30) This is especially challenging in cases of differentiating between functional AKI (HRS and PRA) and structural AKI (ATN), given that features of all three major types of AKI can be present. In this clinical setting, FeUrea can be a valuable "biomarker" given its high diagnostic accuracy (Tables 3 and 4 ). FEUrea could therefore be an informative tool to a clinician in determining the therapeutic approach early. This is likely to be particularly relevant for those with type 1 HRS, where exclusion of ATN with accuracy can allow institution of vasoconstrictor therapy within 24 hours along with albumin infusion. (6) The clinical utility of rapid differential diagnosis of AKI now awaits prospective validation.
There are certain situations that may affect the interpretation of FEUrea. In these situations, such as consumption of a recent high-protein meal and hypercatobolism, the plasma concentration of urea rises disproportionally to serum creatinine. This increases the filtered load of urea, which consequently increases urine urea concentration mirroring prerenal states. (31) However, in such situations, past studies have shown that the differentiation of high urea-producing states from prerenal states could be determined biochemically by a high urine urea/serum creatinine ratio. Here, a ratio much greater than 10 is observed in high ureaproducing conditions. (7, 12) In our cohort, none of the patients with PRA (or HRS) had a urine urea/urine creatinine ratio greater than 10, suggesting that the determined cutoffs of FEUrea are appropriate. Furthermore, it is well accepted that patients with advanced liver disease are malnourished, (32) which advocates that the clinical utility of FEUrea may be ideal in this patient population.
It is important to note that the FEUrea is a simple and widely available tool whose final place in the clinical management of AKI in cirrhosis will need to be defined in additional prospective studies. It is not meant to replace the use of new renal biomarkers, such as neutrophil gelatinase-associated lipocalin, etc., but may allow more selective use of these more expensive analyses. As with any diagnostic test, there are, however, boundaries within which its use must be considered.
In our study, we could not determine whether the presence and/or severity of sarcopenia affects the current diagnostic cutoffs for FEUrea. As such, the effect of sarcopenia would need to be explored in future studies. Second, because of our rigorous inclusion and exclusion criteria, we were unable to evaluate the diagnostic ability of FEUrea in those with PRA who did not respond to therapy (n 5 4). This scenario is often stressful and challenging with regard to clinical management, and thus this subgroup of patients should be evaluated in future studies. Furthermore, even with our extensive adjudication for the type of AKI, there is a possibility of misdiagnosis because we were unable to compare our findings to kidney biopsy, which is considered the gold standard. Although a past study showed that kidney biopsy is safe and supportive in the right clinical setting, (9) they are rarely performed given the concern for bleeding and high risk of complications from an operator's standpoint. Last, we were unable to track changes in FEUrea with response to therapy or worsening of AKI because most patients did not have urinary chemistries on subsequent days of hospital admission. This could be a direct result of anuria or physician practice methods.
In conclusion, in this adjudicated AKI cohort study, FEUrea was found to be an excellent simple tool for the differential diagnosis of AKI in patients with decompensated cirrhosis and ascites. In our study, FEUrea has also proven to be a useful "tubular injury" marker (12) by differentiating ATN from non-ATN with high diagnostic accuracy. However, future studies are needed to compare the noninferiority of FEUrea to other known kidney injury biomarkers to substantiate its role as a useful clinical biomarker. Further prospective studies are also needed to validate its predictive value for AKI progression and to evaluate response to treatment. Ultimately, studies will be needed to demonstrate whether a FEUrea-based early diagnosis alters clinical outcomes.
